Halozyme Therapeutics competitorsClear all

Verastem Oncology's top competitors include Blueprint Medicines and Karyopharm Therapeutics.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Verastem Oncology
Verastem Oncology
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Karyopharm Therapeutics
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
Founding Date
Founding Date
2010
Founding Date
2011
Founding Date
2008
Type
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Needham, US HQ
Walsrode, DE
Locations
Cambridge, US HQ
Amsterdam, NL
Lugano, CH
Zug, CH
Cambridge, US
Locations
Newton, US HQ
München, DE
Giv'atayim, IL
Providence, US
Employees
Employees
4864% decrease
Employees
38376% increase
Employees
4791% decrease
Valuation ($)
Valuation ($)
227.7 m
Valuation ($)
3.4 b
Valuation ($)
N/A
Twitter followers
Twitter followers
2.6 k
Twitter followers
2.6 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
9.2
Average likes per tweet (last 30 days)
5.1
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
92.86%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
182678
Alexa Website Rank
230559
Employee Rating
Employee Rating
N/A
Employee Rating
4.1
Employee Rating
3.6

Financial

Revenue (est.)
Revenue (est.)
$88.5m (FY, 2020)
Revenue (est.)
$793.7m (FY, 2020)
Revenue (est.)
$108.1m (FY, 2020)
Cost of goods
Cost of goods
$33.7m (FY, 2020)
Cost of goods
$425k (FY, 2020)
Cost of goods
N/A
Gross profit
Gross profit
$54.8m (FY, 2020)
Gross profit
$793.3m (FY, 2020)
Gross profit
N/A
Net income
Net income
($67.7m) (FY, 2020)
Net income
$313.9m (FY, 2020)
Net income
($196.3m) (FY, 2020)

Funding

Total funding raised
Total funding raised
$ 170m
Total funding raised
$ 115m
Total funding raised
$ 248.7m
For sources of this data, please see the company profile

View company profiles

Blueprint Medicines
HQ
Cambridge, US
Employees
383

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.

View company
Karyopharm Therapeutics
HQ
Newton, US

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.

View company